Collaborating with NEI Intramural Scientists
The Office of the NEI Technology Development Coordinator assists NEI scientists to exchange research materials, disseminate data, and forge scientific partnerships with industry, academia, and nonprofit organizations. Many of NEI’s technology transfer activities are aimed at developing basic research discoveries to diagnose and/or treat sight threatening diseases. The NEI maintains a list of NEI inventions available for licensing through the NIH Office of Technology Transfer. The SBIR Technology Transfer Program allows small businesses to apply for funding to develop NIH inventions into commercial products and services. If selected for this funding, the small business will be granted a royalty-free, non-exclusive internal research-use license for the NIH-invention. For more information visit the NEI Technology Transfer webpage.
Other NIH Resources to Benefit Translational Vision Research
The Clinical and Translational Science Award (CTSA) program was launched in 2006 and has expanded to about 60 academic medical institutions across the country. CTSA institutions work to accelerate the translation of laboratory discoveries into treatments for patients, to engage communities in clinical research efforts, and to train a new generation of clinical and translational researchers. CTSAs provide facilitate clinical and translational work by providing specialized infrastructure support, engaging community partners, and training the next generation of clinician scientists.
NEI investigators are encouraged to leverage resources available through their local CTSA institution. Over 240 publications supported by the NEI reported receiving additional support from their local CTSA.
Example: CTSA Pilot Funding. In 2012,the Harvard Clinical and Translational Science Center funded Advanced Imaging Pilot Research Grants in two areas of ophthalmology: spectral domain OCT imaging of the optic nerve head and early detection of corneal ectasia.
Example: CTSA Training. All CTSA institutions have a KL2 program, which offers formal research training experience to scholars who already have an M.D., Ph.D., or equivalent doctoral degree. Many CTSA institutions also include programs that provide predoctoral trainees with an introduction to clinical and translational research through the TL1 program.
The Therapeutics for Rare and Neglected Diseases (TRND) program encourages and speeds the development of new drugs for rare and neglected diseases by supporting collaborations among NIH and academic scientists, nonprofit organizations, and pharmaceutical and biotechnology companies. For example, TRND is currently funding research programs to develop a small molecule pharmacological chaperone and to use retinal progenitor cells for the treatment of Retinitis Pigmentosa.
The Blueprint Neurotherapeutics Network (link:) is helping small labs develop new drugs for nervous system disorders. The Network provides research funding, plus access to millions of dollars worth of services and expertise to assist in every step of the drug development process, from laboratory studies to preparation for clinical trials. Project teams across the U.S. have received funding to pursue drugs for conditions from vision loss to neurodegenerative disease to depression. The program is currently funding the development of small molecule drugs for treating dry AMD and the targeting of cytokine-mediated pathologies for neuroprotection in the treatment of AMD.
Translational Research at other NIH Institutes and Centers
- National Center for Advancing Translational Sciences (NCATS)
- National Heart, Lung, and Blood Institute (NHLBI): Office of Translational Alliances and Coordination (OTAC)
- National Institute of Neurological Disorders and Stroke (NINDS): Office of Translational Research
- NIH Center for Regenerative Medicine
- Collaborating with Intramural Investigators at the NIH Clinical Center